Berzosertib

Phase 2Small molecule

Merck & Co.

Berzosertib is one of 180 small molecule programs targeting Lung Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

179

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lung CancerActive, not recruiting

Fallopian Tube CancerActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

Breast CancerActive, not recruiting

Prostate CancerActive, not recruiting

Small Cell Lung CancerActive, not recruiting

Extensive Stage Lung Small Cell CarcinomaActive, not recruiting

Metastatic Fallopian Tube CarcinomaActive, not recruiting

HRD CancerActive, not recruiting

Lung CancerPhase 2

Active, not recruiting

Fallopian Tube CancerPhase 2

Active, not recruiting

Non-Small Cell Lung CancerPhase 1

Active, not recruiting

Breast CancerPhase 1

Active, not recruiting

Prostate CancerPhase 2

Active, not recruiting

Small Cell Lung CancerPhase 1/Phase 2

Active, not recruiting

Extensive Stage Lung Small Cell CarcinomaPhase 2

Active, not recruiting

Metastatic Fallopian Tube CarcinomaPhase 1

Active, not recruiting

HRD CancerPreclinical

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Berzosertib

Merck & Co.

Phase 2

1 2

Megace

Bristol-Myers Squibb

Preclinical

4 3

MS Contin

Merck & Co.

Preclinical

2 4

Lexiscan

Astellas

Preclinical

1 5

Adenocard

Astellas

Preclinical

1 6

Voltaren

Novartis

Preclinical

1 7

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 8

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

1 9

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 10

Conventional Chemotherapy

SShanghai Jiao Tong University School of Medicine

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 2Active, not recruiting

Fallopian Tube Cancer

NCT02595892

Phase 1Active, not recruiting

Non-Small Cell Lung Cancer

NCT02589522

Q1 2027

Phase 2Active, not recruiting

Gastroesophageal Junction Cancer

NCT03641313

Phase 1Active, not recruiting

Breast Cancer

NCT04052555

Phase 1Active, not recruiting

Patients With Solid Tumors

NCT02595931

Q2 2027

Phase 2Active, not recruiting

Extensive Stage Lung Small Cell Carcinoma

NCT03896503

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer2 trials

Testing the Safety of M6620 (VX-970) When Given With Standard Whole Brain Radiation Therapy for the Treatment of Brain Metastases From Non-small Cell Lung Cancer, Small Cell Lung Cancer, or Neuroendocrine Tumors

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT02589522·15 enrolled

Testing the Addition of an Anti-cancer Drug, Berzosertib (M6620, VX-970), to the Usual Treatments (Carboplatin and Gemcitabine) and to Pembrolizumab for Patients With Advanced Squamous Cell Non-small Cell Lung Cancer

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1/2·NCT04216316·12 enrolled

Unresectable Solid Tumor1 trial

Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 1/2·NCT04266912·23 enrolled

Solid Tumors1 trial

Berzosertib Human Mass Balance Study (DDRiver Solid Tumors 208)

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT05246111·6 enrolled

Fallopian Tube Cancer1 trial

Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT02595892·70 enrolled

Metastatic Urothelial Cancer1 trial

Cisplatin and Gemcitabine Hydrochloride With or Without Berzosertib in Treating Patients With Metastatic Urothelial Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT02567409·87 enrolled

11 more indications

Gastroesophageal Junction Cancer1 trial

Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT03641313·17 enrolled

Prostate Cancer1 trial

M6620 and Carboplatin With or Without Docetaxel in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT03517969·73 enrolled

Neuroendocrine Cancer1 trial

Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High-Grade Neuroendocrine Cancers

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1/2·NCT04802174·37 enrolled

Lung Cancer1 trial

Berzosertib + Topotecan in Relapsed Platinum-Resistant Small-Cell Lung Cancer (DDRiver SCLC 250)

Completed· EMD Serono Research & Development Institute, Inc. logo

EMD Serono Research & Development Institute, Inc.·Phase 2·NCT04768296·76 enrolled

Patients With Solid Tumors1 trial

M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT02595931·66 enrolled

Breast Cancer1 trial

Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT04052555·42 enrolled

Head and Neck Cancer1 trial

Testing the Addition of M6620 (VX-970, Berzosertib) to Usual Chemotherapy and Radiation for Head and Neck Cancer

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT02567422·43 enrolled

HRD Cancer1 trial

A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors

Active, not recruiting·NNational Cancer Institute (NCI)·Preclinical·NCT04826341·35 enrolled

Metastatic Fallopian Tube Carcinoma1 trial

Phase 1 Dose Escalation and Expansion Cohort of Carboplatin and Gemcitabine With or Without M6620 (VX-970) in First or Second Recurrence Platinum-Sensitive Epithelial Ovarian, Peritoneal, and Fallopian Tube Cancer

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT02627443·35 enrolled

Extensive Stage Lung Small Cell Carcinoma1 trial

Randomized Phase II Trial of Topotecan Plus M6620 (VX-970, Berzosertib) Vs. Topotecan Alone in Patients With Relapsed Small-Cell Lung Cancer

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT03896503·104 enrolled

Unspecified1 trial

ATRi Transition Rollover Study

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT03309150·1 enrolled

Sources

References

[1]
ClinicalTrials.gov — 17 trial records for Berzosertib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Berzosertib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Berzosertib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Merck & Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Merck & Co.

Berzosertib

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q1 2027

Q2 2027

Trials by Indication[1]

Non-Small Cell Lung Cancer2 trials

Unresectable Solid Tumor1 trial

Solid Tumors1 trial

Fallopian Tube Cancer1 trial

Metastatic Urothelial Cancer1 trial

Gastroesophageal Junction Cancer1 trial

Prostate Cancer1 trial

Neuroendocrine Cancer1 trial

Lung Cancer1 trial

Patients With Solid Tumors1 trial

Breast Cancer1 trial

Head and Neck Cancer1 trial

HRD Cancer1 trial

Metastatic Fallopian Tube Carcinoma1 trial

Extensive Stage Lung Small Cell Carcinoma1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News